The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.
 
Araz Marachelian
Research Funding - Pfizer (Inst); United Therapeutics (Inst)
 
Michael D. Hogarty
No Relationships to Disclose
 
Andrea Flynn
No Relationships to Disclose
 
Kangning Liu
No Relationships to Disclose
 
Eugene W. Gerner
Employment - Cancer Prevention Pharmaceuticals
 
Elizabeth Bruckheimer
Employment - Cancer Prevention Pharmaceuticals
Consulting or Advisory Role - Systems Oncology
 
Anasheh Shamirian
Research Funding - Pfizer (Inst)
 
Charlotte Hasenauer
Research Funding - Pfizer (Inst)
 
Murray Norris
No Relationships to Disclose
 
Michelle Haber
No Relationships to Disclose
 
Susan G. Groshen
Research Funding - Pfizer (Inst)
 
David Simon Ziegler
No Relationships to Disclose
 
Katherine K. Matthay
No Relationships to Disclose